0102
Malunga ne-CAS 103-90-2 Acetaminophen
2024-05-10 09:37:28
| Indawo yokunyibilika | 168-172 °C(lit.) |
| Indawo yokubilisa | 273.17°C (uqikelelo olurhabaxa) |
| ukuxinana | 1,293 g/cm3 |
| uxinzelelo lomphunga | 0.008Pa kwi-25℃ |
| isalathiso se-refractive | 1.5810 (uqikelelo olurhabaxa) |
| Fp | 11 °C |
| ixesha lokugcina. | Umoya ophantsi, uBubushushu beGumbi |
| ukunyibilika | i-ethanol: i-soluble0.5M, icacile, ayinambala |
| pka | 9.86±0.13(Kuxelwe kwangaphambili) |
| ifomu | Iikristale okanye umgubo weCrystalline |
| umbala | Mhlophe |
Inkcazo:
I-acetaminophen, eyaziwa ngokuba yiparacetamol, yikhemikhali yekhemikhali ene-molecular formula C8H9NO2. Iyiyeza eliwela phantsi kweklasi ye-analgesics (i-pain relievers) kunye ne-antipyretics (i-fever reducers). Ngokwesakhiwo, i-acetaminophen yi-para-aminophenol derivative. Ngokubhekiselele kwizakhiwo zomzimba, i-acetaminophen ngumgubo omhlophe wekristale onyibilikayo kancinci emanzini. Ngokuqhelekileyo ifumaneka kwiindlela ezahlukeneyo, kubandakanywa iipilisi, iipilisi, kunye nokumiswa kolwelo, kulawulo lomlomo.
Ukusetyenziswa:
I-acetaminophen isetyenziswa ngokubanzi ukudambisa iintlungu kunye nokunciphisa umkhuhlane. Iyaziwa ngokusebenza kwayo ekudambiseni iintlungu ezingephi ukuya kweziphakathi, njengentloko ebuhlungu, ukuqaqamba kwezihlunu, kunye nokuqaqamba kwamazinyo. Ngokungafaniyo neziyobisi ezichasene ne-nonsteroidal anti-inflammatory (NSAIDs), i-acetaminophen ayinayo iimpawu ezichasene nokudumba.
Indlela echanekileyo yokwenza i-acetaminophen ayiqondwa ngokupheleleyo, kodwa kukholelwa ukuba ibandakanya ukuvinjelwa kwe-enzyme ebizwa ngokuba yi-cyclooxygenase (COX) kwinkqubo ye-nervous central. Le enzyme ibandakanyeka ekuveliseni i-prostaglandin, edlala indima ekuboneni intlungu kunye nokulawula ukushisa komzimba.
I-acetaminophen ithathwa njengeyona ndlela ikhuselekileyo yokunciphisa iintlungu kubantu abangakwaziyo ukunyamezela ii-NSAID ngenxa yezinto ezifana nezilonda zesisu okanye ukuphazamiseka kwegazi.
Uphando olunxulumeneyo:
Izifundo ze-in vitro I-In vitro, i-acetaminophen ibangele i-4.4-fold selectivity ye-COX-2 inhibition (IC50 ye-COX-1, i-113.7 μM; i-IC50 ye-COX-2, i-25.8 μM). Emva kokulawulwa komlomo, ubuninzi be-ex vivo inhibition yi-56% (COX-1) kunye ne-83% (COX-2). I-acetaminophen i-plasma concentrations yahlala ingaphezulu kwe-in vitro IC50 ye-COX-2 ubuncinane kwiiyure ze-5 emva kwe-dosing. Amaxabiso e-ex vivo IC50 e-acetaminophen (COX-1: 105.2 μM; COX-2: 26.3 μM) thelekisa ngokufanelekileyo kunye ne-in vitro IC50 ixabiso. Ngokuchasene neengcamango zangaphambili, i-acetaminophen inqanda i-COX-2 ngaphezu kwe-80%, idigri efaniswa neziyobisi ezingekho phantsi kwe-anti-inflammatory (NSAIDs) kunye ne-COX-2 inhibitors ekhethiweyo. Nangona kunjalo, akukho> 95% i-COX-1 blockade iye yadibaniswa nokuvinjelwa komsebenzi weplatelet [1]. Uvavanyo lwe-MTT lubonise ukuba i-acetaminophen (APAP) kwi-dose ye-50mM kakhulu (p
Izifundo ze-vivo: Ukulawulwa kwe-acetaminophen (250 mg / kg, ngomlomo) kwiigundane kubangele (p